POZEN and AstraZeneca Amend Terms of Collaboration for Pain/Inflammation Combination Product
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 88 (Table of Contents)
Published: 1 Oct-2007
DOI: 10.3833/pdr.v2007.i88.274 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
Just over 13 months after the original deal was made, in August 2006, POZEN and AstraZeneca have mutually agreed to amend certain terms of their collaboration and licence agreement for the development and commercialisation of PN 400, a fixed dose combination of the proton pump inhibitor esomeprazole magnesium with the NSAID, naproxen, in a single tablet...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS